Alcon launches Ilevro

NEW YORK — Eye care company Alcon has launched a treatment for pain and inflammation resulting from cataract surgery, the company said Monday.

The company said Ilevro (nepafenac) ophthalmic suspension was a nonsteroidal anti-inflammatory drug and once-daily treatment for cataract surgery patients.

"We are committed to developing products that continue to improve patient care," Alcon VP and general manager for U.S. pharmaceuticals Gary Menichini said. "This launch represents the dedication of the [research and development] team to engineer and efficacious, innovative formulation with a reduced dosing regimen."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.